AP2013007335A0 - Topical ophthalmological pharmaceutical composition containing regorafenib - Google Patents

Topical ophthalmological pharmaceutical composition containing regorafenib

Info

Publication number: AP2013007335A0
Authority: AP; ARIPO
Prior art keywords: pharmaceutical composition; composition containing; ophthalmological pharmaceutical; topical ophthalmological; containing regorafenib
Prior art date: 2011-06-28

Application number

AP2013007335A

Other languages

English (en)

Inventor

Julia Freundlieb

Michael Bottger

Claudia Hirth-Dietrich

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-28

Filing date

2012-06-26

Publication date

2013-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013007335(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-26 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2013-12-31 Publication of AP2013007335A0 publication Critical patent/AP2013007335A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AP2013007335A 2011-06-28 2012-06-26 Topical ophthalmological pharmaceutical composition containing regorafenib AP2013007335A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11171719		2011-06-28
EP12155281		2012-02-14
PCT/EP2012/062365 WO2013000917A1 (fr)	2011-06-28	2012-06-26	Composition pharmaceutique topique ophtalmologique contenant du régorafénib

Publications (1)

Publication Number	Publication Date
AP2013007335A0 true AP2013007335A0 (en)	2013-12-31

Family

ID=46456546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2013007335A AP2013007335A0 (en)	2011-06-28	2012-06-26	Topical ophthalmological pharmaceutical composition containing regorafenib

Country Status (26)

Country	Link
US (1)	US20140296301A1 (fr)
EP (1)	EP2726059A1 (fr)
JP (1)	JP5998213B2 (fr)
KR (1)	KR20140048218A (fr)
CN (1)	CN103889399A (fr)
AP (1)	AP2013007335A0 (fr)
AR (1)	AR086800A1 (fr)
AU (1)	AU2012277905A1 (fr)
BR (1)	BR112013033831A2 (fr)
CA (1)	CA2840329A1 (fr)
CL (1)	CL2013003700A1 (fr)
CO (1)	CO6920289A2 (fr)
CR (1)	CR20130693A (fr)
CU (1)	CU24163B1 (fr)
DO (1)	DOP2013000314A (fr)
EA (1)	EA201400064A1 (fr)
EC (1)	ECSP13013106A (fr)
GT (1)	GT201300322A (fr)
HK (1)	HK1197176A1 (fr)
MX (1)	MX2013015287A (fr)
PE (1)	PE20141031A1 (fr)
PH (1)	PH12013502691A1 (fr)
TN (1)	TN2013000533A1 (fr)
UY (1)	UY34166A (fr)
WO (1)	WO2013000917A1 (fr)
ZA (1)	ZA201400646B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA91520C2 (en)	2004-09-29	2010-08-10	Баер Шеринг Фарма Акциенгезельшафт	Thermodynamically stable form of tosylate
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) *	2012-12-21	2014-07-31	Bayer Healthcare Llc	Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (fr) *	2013-07-24	2015-01-29	Dr. Reddys Laboratories Limited	Formes polymorphes cristallines du régorafénib et méthodes de préparation de la forme polymorphe i du régorafénib
CN103923000A (zh) *	2014-01-29	2014-07-16	苏州晶云药物科技有限公司	几种新晶型及其制备方法
CN104546776B (zh) *	2015-02-10	2017-08-22	杭州朱养心药业有限公司	瑞戈非尼片剂药物组合物和制法
CN108135737B (zh) *	2015-06-06	2021-11-05	拨云生物医药科技(广州)有限公司	用于治疗翼状胬肉的组合物和方法
CA3026118A1 (fr)	2016-06-02	2017-12-07	Cloudbreak Therapeutics, Llc	Compositions et methodes d'utilisation de nintedanib pour le traitement de maladies oculaires a neovascularisation anormale

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2732222B1 (fr) *	1995-03-28	1997-04-25	Oreal	Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
AU2003240719B2 (en) *	2002-05-28	2009-12-10	Astrazeneca Ab	Ophthalmological use of roflumilast for the treatment of diseases of the eye
SI1663978T1 (sl)	2003-07-23	2008-02-29	Bayer Pharmaceuticals Corp	Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj
ZA200709251B (en)	2005-05-10	2009-08-26	Alcon Inc	Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
JP2008543775A (ja)	2005-06-08	2008-12-04	ターゲジェンインコーポレーティッド	眼の障害を治療するための方法および組成物
BRPI0619057A2 (pt)	2005-11-29	2011-09-20	Smithkline Beecham Corp	formulação farmacêutica de uso tópico, uso de um ou mais compostos, e, compostos
JP2009519267A (ja) *	2005-12-15	2009-05-14	バイエル・ヘルスケア・アクチェンゲゼルシャフト	炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア
US20070149593A1 (en)	2005-12-23	2007-06-28	Alcon, Inc.	PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (fr)	2006-08-30	2008-03-06	Merck & Co., Inc.	Formulations ophtalmiques locales
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100130569A1 (en) *	2007-05-11	2010-05-27	Saten Pharmaceutical Co., Ltd.	Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
DE102007055341A1 (de) *	2007-11-19	2009-05-20	Bayer Animal Health Gmbh	Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
JP2012525415A (ja)	2009-05-01	2012-10-22	オプソテツク・コーポレイシヨン	眼科疾患を処置または予防するための方法
CA2768237A1 (fr)	2009-07-16	2011-01-20	Glaxo Wellcome Manufacturing Pte Ltd	Methode de traitement

2012
- 2012-06-26 JP JP2014517661A patent/JP5998213B2/ja not_active Expired - Fee Related
- 2012-06-26 AU AU2012277905A patent/AU2012277905A1/en not_active Abandoned
- 2012-06-26 US US14/128,356 patent/US20140296301A1/en not_active Abandoned
- 2012-06-26 PH PH1/2013/502691A patent/PH12013502691A1/en unknown
- 2012-06-26 CU CU20130168A patent/CU24163B1/es active IP Right Grant
- 2012-06-26 WO PCT/EP2012/062365 patent/WO2013000917A1/fr not_active Ceased
- 2012-06-26 EP EP12731396.3A patent/EP2726059A1/fr not_active Withdrawn
- 2012-06-26 CN CN201280042504.9A patent/CN103889399A/zh active Pending
- 2012-06-26 HK HK14110517.7A patent/HK1197176A1/xx unknown
- 2012-06-26 MX MX2013015287A patent/MX2013015287A/es not_active Application Discontinuation
- 2012-06-26 AP AP2013007335A patent/AP2013007335A0/xx unknown
- 2012-06-26 KR KR1020147002095A patent/KR20140048218A/ko not_active Withdrawn
- 2012-06-26 BR BR112013033831A patent/BR112013033831A2/pt not_active IP Right Cessation
- 2012-06-26 CA CA2840329A patent/CA2840329A1/fr not_active Abandoned
- 2012-06-26 EA EA201400064A patent/EA201400064A1/ru unknown
- 2012-06-26 PE PE2013002872A patent/PE20141031A1/es not_active Application Discontinuation
- 2012-06-27 UY UY0001034166A patent/UY34166A/es not_active Application Discontinuation
- 2012-06-28 AR ARP120102339A patent/AR086800A1/es unknown
2013
- 2013-12-20 CR CR20130693A patent/CR20130693A/es unknown
- 2013-12-23 CL CL2013003700A patent/CL2013003700A1/es unknown
- 2013-12-23 GT GT201300322A patent/GT201300322A/es unknown
- 2013-12-24 EC EC2013013106A patent/ECSP13013106A/es unknown
- 2013-12-26 CO CO13300167A patent/CO6920289A2/es not_active Application Discontinuation
- 2013-12-26 DO DO2013000314A patent/DOP2013000314A/es unknown
- 2013-12-27 TN TNP2013000533A patent/TN2013000533A1/fr unknown
2014
- 2014-01-27 ZA ZA2014/00646A patent/ZA201400646B/en unknown

Also Published As

Publication number	Publication date
HK1197176A1 (en)	2015-01-09
GT201300322A (es)	2014-11-13
CR20130693A (es)	2016-05-02
MX2013015287A (es)	2014-03-31
TN2013000533A1 (en)	2015-03-30
CU20130168A7 (es)	2014-04-24
CL2013003700A1 (es)	2014-07-18
AU2012277905A1 (en)	2014-01-16
AU2012277905A8 (en)	2014-01-30
PH12013502691A1 (en)	2017-08-23
JP2014518233A (ja)	2014-07-28
BR112013033831A2 (pt)	2017-02-14
CO6920289A2 (es)	2014-04-10
KR20140048218A (ko)	2014-04-23
ECSP13013106A (es)	2014-01-31
WO2013000917A1 (fr)	2013-01-03
DOP2013000314A (es)	2014-04-15
EA201400064A1 (ru)	2014-05-30
PE20141031A1 (es)	2014-08-21
CN103889399A (zh)	2014-06-25
NZ619229A (en)	2016-04-29
EP2726059A1 (fr)	2014-05-07
JP5998213B2 (ja)	2016-09-28
UY34166A (es)	2013-01-31
AR086800A1 (es)	2014-01-22
CU24163B1 (es)	2016-03-31
ZA201400646B (en)	2015-11-25
US20140296301A1 (en)	2014-10-02
CA2840329A1 (fr)	2013-01-03

Publication	Publication Date	Title
AP3864A (en)	2016-10-31	Pharmaceutical composition
ZA201501394B (en)	2016-07-27	Coated pharmaceutical composition containing regorafenib
GB201118232D0 (en)	2011-12-07	Pharmaceutical composition
SG11201400580VA (en)	2014-05-29	Pharmaceutical composition for inhalation
ZA201400646B (en)	2015-11-25	Topical ophthalmological pharmaceutical composition containing regorafenib
ZA201308157B (en)	2015-01-28	Pharmaceutical composition
ZA201306395B (en)	2014-04-30	New low side effect pharmaceutical composition containing antituberculosis drugs
EP2685993A4 (fr)	2014-11-19	Compositions pharmaceutiques et utilisation topique de celles-ci
ZA201306905B (en)	2014-12-23	Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
ZA201505196B (en)	2017-11-29	Topical ophthalmological pharmaceutical composition containing regorafenib
ZA201302012B (en)	2014-04-30	Low dose pharmaceutical composition
EP2727593A4 (fr)	2014-11-26	Composition pharmaceutique contenant du nicorandil
EP2711010A4 (fr)	2015-04-15	Composition pharmaceutique
EP2851074A4 (fr)	2015-06-17	Composition pharmaceutique analgésique
IL227651A (en)	2017-02-28	Topical pharmacological formulations containing 220b
HUP1100444A2 (en)	2013-02-28	Pharmaceutical composition
HUP1100445A2 (en)	2013-02-28	Pharmaceutical composition
HK40096792A (en)	2024-03-01	Coated pharmaceutical composition containing regorafenib
HK40096791A (en)	2024-03-01	Coated pharmaceutical composition containing regorafenib
HK40096793A (en)	2024-03-01	Coated pharmaceutical composition containing regorafenib
ZA201309537B (en)	2015-04-29	Pharmaceutical composition comprising fexofedine
AU2011905393A0 (en)	2012-01-19	Pharmaceutical Composition
AU2012904295A0 (en)	2012-10-18	Pharmaceutical composition
HK1191243A (en)	2014-07-25	Pharmaceutical composition comprising fexofenadine